BioMedTracker's JPM Drug News: Day 3
This article was originally published in Scrip
Executive Summary
Every day of the 34th annual JP Morgan Healthcare Conference in San Francisco, analysts from BioMedTracker – an affiliate of Scrip Intelligence – produce a report detailing the drug events and catalysts that are announced or updated at the meeting. See below for the highlights, and click on the link at the bottom for a complimentary copy of the full report.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.